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incidence (assuming 1 occurrence/patient/cycle), treatment usage, and 1-year 
prevalence of MM (2124 cases) to estimate the treatment burden in Australia for a 
single AE occurrence. Results: The most cost-intensive AEs were all Gr 3/4. For TT, 
the most cost-intensive AEs were squamous cell carcinoma (SCC) and rash, with 
a mean cost per event per patient of A$228 and A$223, respectively. For IT, they 
were colitis and diarrhea, with a mean cost of A$1471 and A$1333, respectively. 
For CT, they were neutropenia/leukopenia and anaphylaxis, representing a mean 
cost of A$1005 and A$381, respectively. Across all 3 treatment categories, the top 
4 AEs with the highest burden were all Gr 3/4 and included neutropenia/leukope-
nia (mean total cost of A$92,453), colitis (A$72,346), diarrhea (A$69,399), and SCC 
(A$30,636). ConClusions: In Australia, costs for management of AEs associated 
with MM therapies can be substantial. Since we did not account for multiple AE 
occurrences, the total burden is likely to be an underestimate.
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objeCtives: To understand the proportion of total medical costs attributed to can-
cer drug treatment in oncology patients, with a focus on breast and prostate can-
cer. Methods: Literature review conducted using PubMed, Medscape and Google 
to identify and retrieve studies in cancer patients reporting total medical costs and 
cost components, particularly cancer drug treatment costs. All studies reporting 
data on US American patients published in English language between 2009 and 2013 
were included. Results: A total of 5565 studies were reviewed, 14 of which were 
relevant and included. Total medical costs and cost components varied substantially 
by tumor type and location, cancer stage, phase of care, study design, payers and 
the way drug and treatment costs were defined and reported. In 2011, oncology 
care costs accounted for $125 billion. Prescription drug costs were 1.8–13.9% of total 
cancer care costs, with 13.9% representing the proportion of costs during the last six 
months of life. Studies of breast cancer patients reported that drugs accounted for 
2.4–37.0% of total costs, with the lowest proportion occurring in newly diagnosed 
and the highest in metastatic patients, respectively. Outpatient visits were the pri-
mary cost driver, accounting for 64.0-82.0% of total costs. Among patients receiving 
chemotherapy as their primary treatment, chemotherapy costs accounted for 25.0% 
and other medications (e.g., analgesics, sedatives, anti-emetics, antidepressants) 
accounted for 26.0% of total costs. None of the prostate cancer studies identified met 
the research inclusion criteria. ConClusions: Studies on drug treatment costs are 
limited and results vary substantially depending on patient clinical characteristics, 
cancer stage, and disease progression. Existing studies suggest that although medi-
cal costs are high overall, cancer drug treatment costs only contribute 1.8–13.9% of 
total cancer costs, and 2.4–37.0% in breast cancer.
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objeCtives: Manufacturer listed prices do not represent real transactions prices 
but are often used to set up reimbursement rates for third-party payers. This study 
evaluates approvals, discontinuations, and price trends of oncology drugs approved 
by the US Food and Drug Administration (FDA) in the period 1990-2013. Methods: 
Drug regulatory information derived from the FDA. Average wholesaler prices (AWP) 
per unit were collected from the RedBook. Annual average price changes were cal-
culated for each drug as the increase in prices from market entry to Dec-31-2013 
divided by the number of years between the effective dates of those prices. Prices 
were converted to 2013 year dollars using the consumer price index (CPI). Descriptive 
statistics and 95% confidence intervals and t-tests were performed in the analy-
sis. Results: The FDA listed 165 approved oncology therapeutic drugs (44 biologics 
and 121 chemical entities) in the period of analysis. The FDA approved 31 products 
(18% of total) before the 1980s, 11 (6.7%) in the 1980s, 50 (30.3%) in the 1990s, 48 
(29.1%) in the 2000s, and 25 (15.2%) in 2010-2103. There were 45 (27.3%) products 
with at least one FDA approved orphan indication. There were 10 products (6.1% 
of approvals) discontinued. There were 45 products with complete price history 
from approval to January 1,2014, and 2 had generic competition. The CPI adjusted 
average annual AWP price increase was 10.2%±21.0% (95%CI:8.2%-12.1%); with an 
average 9.18±6.59 years in the market. The average annual AWP increase was higher 
for products approved in the 1990s (20.9%±34.8%) than for those approved in the 
2000’s (5.0%±5.2%) and 2000-2013 (6.3%±9.8%). Chemical entities and drugs with 
orphan indications had higher AWP price increases than biologics and non-orphan 
drugs, respectively. ConClusions: Manufacturer listed prices of oncology products 
approved in the period 1990-2013 grew faster than the inflation. Price increases were 
higher for orphan drugs and chemical entities.
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objeCtives: Since approval of imatinib, systemic therapy (ST) for gastrointestinal 
stromal tumors (GIST) has changed considerably. This study evaluated treatment pat-
terns and costs across 3 large retrospective databases among GIST patients receiv-
(IRR= 2.68); BV had higher proteinuria (IRR= 0.64; p< 0.01). GI perforation incidence 
rates trended higher (p> 0.05) with BV (LOT1:0.02 vs. 0; LOT2:0.001 vs. 0). BV patients 
had lower per-patient per-month (PPPM) total costs (LOT1 adj. difference: –$4,202, 
p< 0.01; LOT2: -$3,776, p= 0.01), and PPPM AE medical costs (LOT1:-$5,851, p< 0.01; 
LOT2: –$4,293, p= 0.02). ConClusions: BV during first or second line mCRC treat-
ment was associated with lower AE rates and lower PPPM costs compared to CET. 
Limitations include the inability to distinguish events related to targeted vs. chemo 
agents and high baseline rates of certain events (e.g., hypertension).
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objeCtives: Early stage breast cancer is treated with surgery plus adjuvant ther-
apy which may include radiation, cytotoxic chemotherapy, and hormonal therapy 
resulting in substantial cost variation. Understanding costs is essential to estab-
lishing aberrant billing and clinical practice variation. Methods: This naturalistic 
study assessed 10 million commercial members younger than 65. Claims data from 
January 2009 through December 2012 was assessed. During 2010-2011, members 
with primary breast cancer surgery, defined as the first diagnosis coded breast can-
cer claim lumpectomy or mastectomy claim and continuous enrollment > = 365 days 
before and after surgery were identified and categorized into three groups: receiving 
no chemotherapy, cytotoxic chemotherapy without trastuzumab, or chemotherapy 
including trastuzumab. Members were excluded if there was claims evidence for 
metastatic breast cancer or any radiation therapy before surgery. The start date was 
the first cytotoxic chemotherapy claim, if it occurred prior to surgery, otherwise it 
was the surgery date. Medical and pharmacy claims expenses were summed for 
the post 365-day interval beginning at the earlier of the surgery date or start of 
neoadjuvant chemotherapy. Results: 5,050 members met analysis criteria; 2,437 
(48.3%) no chemotherapy, 1,965 (38.9%) chemotherapy without trastuzumab, and 648 
(12.8%) chemotherapy plus trastuzumab, and average medical plus pharmacy claims 
expense for members in these categories for the 365-day interval was $49,392, 
$99,646, and $169,083, respectively. Average chemotherapy costs for members receiv-
ing chemotherapy without trastuzumab (n= 1,965) was $11,695 and for members 
with trastuzumab (n= 648) $74,048. ConClusions: The cost of early stage breast 
cancer therapy varies by the three described treatment categories. Compared with 
the no chemotherapy group, average expenses for all medical and pharmacy claims 
in a 365-day interval was $50,254 higher for members who received chemotherapy 
without trastuzumab, and $119,691 higher for the group with chemotherapy includ-
ing trastuzumab. Member cost distributions between and within these categories 
will be helpful in developing managed care strategies.
PCN77
eCoNoMiC burdeN of adverse effeCts assoCiated with MetastatiC 
MeLaNoMa (MM) treatMeNts iN the uNited KiNgdoM
Vouk K.1, Benter U.1, Amonkar M.2, Stapelkamp C.3
1INC Research GmbH, Munich, Germany, 2GlaxoSmithKline, Collegeville, PA, USA, 
3GlaxoSmithKline, Uxbridge, UK
objeCtives: Chemotherapy (CT), targeted therapy (TT), and immunotherapy (IT), 
which are commonly used to treat MM, are often associated with adverse effects 
(AEs). This study estimated the per-event cost and economic burden associated 
with managing the most common and/or severe AEs for these 3 treatment cat-
egories from the UK National Health Service perspective. Methods: A literature 
review evaluated the incidence and types of AEs associated with the 3 treatment 
categories. A total of 29 AEs (CT:11; TT:11; and IT:7), all-severity grades (Gr) occurring 
in > 20% or Gr 3/4 occurring in > 5%, were selected. Medical resource use related to 
the management of AEs was assessed by conducting 2 blinded Delphi panel cycles 
with 4 clinicians. Published unit costs were used to estimate the costs per AE and 
then combined with AE incidence (assuming 1 occurrence/patient/cycle), treatment 
usage, and 1-year prevalence of MM (2027 cases) to estimate treatment burden in the 
UK for a single AE occurrence. Results: For CT, the most cost-intensive AEs were 
Gr 3/4 peripheral neuropathy and thrombocytopenia, representing a mean cost per 
event per patient of £432 and £277, respectively. For TT, they were Gr 3/4 squamous 
cell carcinoma (SCC) and Gr 1/2 skin papilloma, with a mean cost of £1281 and £845, 
respectively. For IT, they were Gr 3/4 diarrhea and colitis, both with a mean cost 
of £2836. The top 5 AEs with the highest treatment burden across all 3 categories 
included Gr 3/4 SCC (mean total cost of £202,493), Gr 3/4 diarrhea (£132,032), Gr 
1/2 skin papilloma (£125,995), Gr 3/4 colitis (£124,695) and Gr 3/4 immune-related 
hypophysitis (£98,393), and Gr 1/2 hyperkeratosis (£70,292). ConClusions: In the 
UK, costs for management of AEs associated with MM therapies can be substantial. 
The total burden may be underestimated since it does not account for AE recurrence.
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objeCtives: Targeted therapy (TT), immunotherapy (IT), and chemotherapy (CT), 
which are commonly used in the treatment of MM, are frequently associated with 
adverse effects (AEs). This study estimated the per-event cost and economic burden 
associated with managing the most common and/or severe AEs for these 3 treat-
ment categories from the Australian statutory health insurance system perspec-
tive. Methods: The study involved a literature review to evaluate the incidence 
and types of AEs associated with the 3 treatment categories. A total of 29 AEs (CT:11; 
TT:11; and IT:7), all-severity grades (Gr) occurring in > 20% or Gr 3/4 occurring in 
> 5%, were selected. Medical resource use related to the management of AEs was 
assessed by conducting 2 blinded Delphi panel cycles with 5 clinicians. Published 
unit costs were used to estimate the costs per AE and then combined with AE 
